Seeing Is Believing
Currently out of the existing stock ratings of David Westenberg, 125 are a BUY (63.45%), 66 are a HOLD (33.5%), 6 are a SELL (3.05%).
Analyst David Westenberg, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 52.01% that have a potential upside of 19.12% achieved within 113 days.
David Westenberg’s has documented 399 price targets and ratings displayed on 22 stocks. The coverage is on Healthcare, Financial Services sectors.
Most recent stock forecast was given on AKYA, Akoya Biosciences at 14-Apr-2025.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/13/2023. The price target of $3 was fulfilled within 1 day with a profit of $0.24 (8.7%) receiving and performance score of 86.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$16
$-1.86 (-10.41%)
$22
1 months 18 days ago
(04-Mar-2025)
4/12 (33.33%)
$0.72 (4.71%)
82
Hold
$27
$9.14 (51.18%)
$25
8 months 17 days ago
(05-Aug-2024)
1/6 (16.67%)
$3.33 (14.07%)
156
Buy
$125
$107.14 (599.89%)
$141
3 years 2 months 28 days ago
(25-Jan-2022)
3/7 (42.86%)
$61.5 (96.85%)
87
Buy
$140
$122.14 (683.87%)
$140
3 years 8 months 12 days ago
(10-Aug-2021)
6/9 (66.67%)
$42.66 (43.83%)
90
Sell
$65
$28.11 (76.20%)
$55
3 years 8 months 12 days ago
(10-Aug-2021)
6/8 (75%)
$-21.64 (-24.36%)
252
Which stock is David Westenberg is most bullish on?
Which stock is David Westenberg is most reserved on?
What Year was the first public recommendation made by David Westenberg?